Second Recent Breakthrough Publication Where IsoPlexis’ Single-Cell Functional Phenotyping Predicts Persistence in Cutting Edge Cell Therapies in Solid Tumor

Gastroenterology Journal, Feb ‘20: “Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice”

Another high impact study showing T cell persistence in solid tumor was recently published using IsoPlexis’ single-cell functional phenotyping technology. Published in Gastroenterology, the article “Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice” comes on the heels of a recent publication in Nature Communications where IsoPlexis’ single-cell functional phenotyping correlated with T cell persistence in solid tumor.

While CAR-T treatments have done relatively well so far in treating B cell malignancies, the conversion to treating solid tumors with CAR-T cells remains a challenge. Glypican-3 (GPC3) is a protein that’s expressed in over 70% of hepatocellular carcinoma (HCC) and other solid tumors, and because it can promote tumor growth, CAR-T cells and bispecific antibodies targeting GPC3 have been developed. This study sought to improve the anti-tumor activity and further modified the CAR construct, in which IsoPlexis’ functional single-cell metrics correlated with persistence of the CAR-T cells in solid tumor.

Insights into Developing Cutting Edge CAR-T Products Targeting Difficult to Treat Liver Cancer Using IsoPlexis’ Single-Cell Functional Phenotyping:

  • Demonstration of a uniquely positive correlation of enhanced polyfunctionality by single-cell IsoCode proteomics with persistence of T cell response and in vivo killing capacity of GPC3-specific humanized YP7 (hYP7) CAR-T cell products to HCC.
  • Earlier information on T cell polyfunctional capacity provides clear value for choice in development of cell therapies against solid tumor.
  • Correlation of enhanced polyfunctionality by single-cell IsoCode proteomics with an in vitro killing capacity of these CAR-T cell products to HCC.
  • As far as uncovering the biological drivers, single-cell functional phenotyping revealed the superior antitumor mechanisms of GPC3-targeted hYP7 CAR-T cell products in inhibiting Wnt signaling and promoting the perforin/granzyme-mediated apoptosis in tumor cells through enhanced polyfunctional CD8+ T cells subsets identified by single-cell functional proteomics.
  • Importantly, researchers demonstrate the antigen-driven persistence and expansion of polyfunctional hYP7 CAR-T cells in the tumor microenvironment which cause tumor regression in HCC mouse models, providing a novel therapeutic candidate of hYP7 CAR-T products for the treatment of patients with liver cancer.


(data from Li et al. Gastroenterology, 2020)

Discovery of Polyfunctionality and Immune Persistence in Solid Tumor Enabled by IsoPlexis’ Single-Cell Proteomics

The researchers in this study used the proteomically barcoded IsoCode technology to functionally characterize the CAR-T constructs. The hPY7 CAR-T cells demonstrated remarkably higher PSI than the HN3 CAR-T cells when stimulated with either Hep3B or G1 cells. Furthermore, CD8+ hYP7 CAR-T cells had a PSI 8 to 11 times higher than the CD4+ hYP7 CAR-T cells co-cultured with Hep3B and G1 cells. This indicated that the CD8+ CAR-T cells were more polyfunctional than the CD4+ CAR-T cells. The researchers also discovered that HCC patient-derived polyfunctional CD8+ hYP7 CAR-T cells contained effector cytokines (granzyme B, IFN-γ, perforin) as well as cytokines not secreted by CD8+ hYP7 CAR-T cells from healthy donors (TNF-α, MIP-1β, and IL-8). 66% of mice treated with the hYP7 CAR-T cells had their tumors eliminated by week 3, while mice treated with the HN3 CAR-T cells did not have a reduction in tumor burden. The hYP7 CAR-T treated mice also continued to be free of tumors after additional Hep3B cells were introduced. IsoPlexis’ single-cell functional phenotyping was able to reveal critical functional drivers that correlated to CAR-T cell persistence in solid tumor.

CAR-T Mice

(data from Li et al. Gastroenterology, 2020)

Read the “Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice” article in Gastroenterology here. IsoPlexis’ proteomic hub has become a standard in many leading global labs and the IsoLight and chip product suite have already helped to accelerate numerous therapy programs. Speak to a single-cell functional proteomics expert today to see what IsoPlexis’ proteomic solutions can do for you.

IsoPlexis IsoLight
Speak to an Expert
Speak to a cellular proteomics expert to learn how our data is empowering what’s next in your research area.
Share This Article
Be in the Know.
Unlock Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.